The efficacy and safety of daclizumab and its potential role in the treatment of multiple sclerosis
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The efficacy and safety of daclizumab and its potential role in the treatment of multiple sclerosis
Authors
Keywords
-
Journal
Therapeutic Advances in Neurological Disorders
Volume 7, Issue 1, Pages 7-21
Publisher
SAGE Publications
Online
2013-09-13
DOI
10.1177/1756285613504021
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial
- (2013) Ralf Gold et al. LANCET
- Natalizumab Therapy for Multiple Sclerosis
- (2013) Jeremy Chataway et al. Neurotherapeutics
- Daclizumab Use in Patients With Pediatric Multiple Sclerosis
- (2012) Mark P. Gorman ARCHIVES OF NEUROLOGY
- Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial
- (2012) Jeffrey A Cohen et al. LANCET
- Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial
- (2012) Alasdair J Coles et al. LANCET
- Systematic review of disease-modifying therapies to assess unmet needs in multiple sclerosis: tolerability and adherence
- (2012) G Giovannoni et al. Multiple Sclerosis Journal
- CD56bright Natural Killer Cell Expansion Predicts Response to Daclizumab HYP Treatment in RRMS: Results of the SELECT Trial (S31.004)
- (2012) J. Elkins et al. NEUROLOGY
- Clinical Efficacy of Laquinimod for the Treatment of Multiple Sclerosis; Pooled Analyses from the ALLEGRO and BRAVO Phase III Trials (S01.007)
- (2012) T. Vollmer et al. NEUROLOGY
- Daclizumab Therapy for Multiple Sclerosis
- (2012) Bibiana Bielekova Neurotherapeutics
- Placebo-Controlled Phase 3 Study of Oral BG-12 or Glatiramer in Multiple Sclerosis
- (2012) Robert J. Fox et al. NEW ENGLAND JOURNAL OF MEDICINE
- Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis
- (2012) Ralf Gold et al. NEW ENGLAND JOURNAL OF MEDICINE
- Inhibition of LTi Cell Development by CD25 Blockade Is Associated with Decreased Intrathecal Inflammation in Multiple Sclerosis
- (2012) J. S. A. Perry et al. Science Translational Medicine
- The effect of daclizumab on brain atrophy in relapsing-remitting multiple sclerosis
- (2012) Isabela T. Borges et al. Multiple Sclerosis and Related Disorders
- Anti-CD25 (daclizumab) monoclonal antibody therapy in relapsing–remitting multiple sclerosis
- (2011) Roland Martin CLINICAL IMMUNOLOGY
- Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial
- (2011) Ludwig Kappos et al. LANCET
- A role for interleukin-2 trans-presentation in dendritic cell–mediated T cell activation in humans, as revealed by daclizumab therapy
- (2011) Simone C Wuest et al. NATURE MEDICINE
- Intrathecal effects of daclizumab treatment of multiple sclerosis
- (2011) B. Bielekova et al. NEUROLOGY
- Randomized Trial of Oral Teriflunomide for Relapsing Multiple Sclerosis
- (2011) Paul O'Connor et al. NEW ENGLAND JOURNAL OF MEDICINE
- An IL-2 Paradox: Blocking CD25 on T Cells Induces IL-2-Driven Activation of CD56bright NK Cells
- (2010) J. F. Martin et al. JOURNAL OF IMMUNOLOGY
- Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta
- (2010) Daniel Wynn et al. LANCET NEUROLOGY
- Single-cell quantification of IL-2 response by effector and regulatory T cells reveals critical plasticity in immune response
- (2010) Ofer Feinerman et al. Molecular Systems Biology
- Regulatory T Cells Are Reduced During Anti-CD25 Antibody Treatment of Multiple Sclerosis
- (2009) Unsong Oh et al. ARCHIVES OF NEUROLOGY
- Effect of Anti-CD25 Antibody Daclizumab in the Inhibition of Inflammation and Stabilization of Disease Progression in Multiple Sclerosis
- (2009) Bibiana Bielekova et al. ARCHIVES OF NEUROLOGY
- Daclizumab in treatment of multiple sclerosis patients
- (2009) EN Ali et al. Multiple Sclerosis Journal
- Monoclonal antibodies in MS: Mechanisms of action
- (2009) B. Bielekova et al. NEUROLOGY
- CD56brightnatural killer (NK) cells: an important NK cell subset
- (2008) Aurélie Poli et al. IMMUNOLOGY
- B-Cell Depletion with Rituximab in Relapsing–Remitting Multiple Sclerosis
- (2008) Stephen L. Hauser et al. NEW ENGLAND JOURNAL OF MEDICINE
- Review: Innovative monoclonal antibody therapies in multiple sclerosis
- (2008) Ralf A. Linker et al. Therapeutic Advances in Neurological Disorders
- The Biology of Interleukin-2
- (2007) Thomas R. Malek Annual Review of Immunology
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More